In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...
The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 Agonists
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...
The Allegations: Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo's Phase 3 CagriSema Study on Obesity According to the complaint ...
On 21 December of last year, the Danish pharmaceutical company experienced a 21% plunge in its share price following disappointing trial results for its new obesity drug, CagriSema. Amycretin is ...
The Allegations: Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo's Phase 3 CagriSema Study on Obesity About Robbins LLP ...
Investors had dumped Novo shares in late December when data on a highly touted experimental Novo weight-loss shot called CagriSema fell far short of the expectations the company had set.
Twice in the past two months, investors have been disappointed by the numbers -- 22.7% average weight loss over 68 weeks for CagriSema, and 20.7% weight loss for a 72-week regimen of semaglutide 7 ...
Just over a month after its CagriSema readout disappointed analysts, Novo Nordisk released promising data for its obesity drug amycretin. The Danish pharmaceutical giant ended off the week on a high ...
Researchers from the Institute of Science Tokyo and Osaka Medical and Pharmaceutical University said that they have developed a peptide that can bind to the spike proteins of SARS-CoV-2 to prevent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback